Suven Life Sciences share price
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹261.40down ₹0.60 (0.23%)BSE ₹261.55
Share price at the NSE close on 27 Oct 2026. Previous close ₹262.00.
27 Oct: open ₹262.00, high ₹265.75, low ₹259.45
52-week range of traded prices to 27 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,386 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,98,99152.2% delivered
Results
Consolidated; ₹ crore.Suven Life Sciences quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +17.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3.57 Crup 134.58%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹128 CrQuarter to Mar 2026: −₹46 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −3,578.7%
Revenue by quarter
Peak revenue ₹3.57 Cr, quarter to Jun 2026; lowest ₹0.92 Cr, quarter to Sep 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 8 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Net profit | −50 | −39 | −44 | −52 | −77 | −102 | −46 | −128 |
| Net margin | −1,929.5% | −2,429.8% | −2,995.6% | −2,759.8% | −8,410.6% | −3,628.8% | −2,999.5% | −3,578.7% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹7.11 Crup 6.89%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹276 CrYear to Mar 2025: −₹161 Cr
- Net margin
- −3,884.1%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 7 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹14 Cr, differs from its quarters added, ₹485 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 544 | 625 | 664 | 14 | 13 | 12 | 14 | 12 | 7 | 7 |
| Net profit | 87 | 124 | 87 | −94 | −72 | −122 | −118 | −105 | −161 | −276 |
| Net margin | 16.0% | 19.8% | 13.1% | −653.6% | −535.3% | −1,030.0% | −873.5% | −898.6% | −2,415.1% | −3,884.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Its history crosses a change of basis in the accounts in the year to Mar 2020: days before it are of the company before the change.Suven Life Sciences PE ratio and valuation
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 66% of 2,412 trading days over the last 10 years.
LowestHighest
Its median0.00%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +15.9% | – | – | 0.0% |
| 3 years | +39.5% | – | – | 0.0% |
| 5 years | +13.3% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
9 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 3 of the 3 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 6
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
- CutCut. Funds that held fewer shares than at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 2,00,494 | 0.27% | ₹6.42 Cr |
| Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 2,060 | 0.15% | ₹0.07 Cr |
 Groww Nifty Total Market Index FundGroww Mutual Fund | 1,310 | 0.01% | ₹0.04 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 971 | 0.15% | ₹0.03 Cr |
| Motilal Oswal BSE 1000 Index FundMotilal Oswal Mutual Fund | 218 | 0.01% | ₹70,000 |
 Angel One Nifty Total Market Index FundAngel One Mutual Fund | 218 | 0.01% | ₹69,800 |
 Mirae Asset Nifty Total Market Index FundMirae Asset Mutual Fund | 180 | 0.01% | ₹58,000 |
| Bandhan Nifty Total Market Index FundBandhan Mutual Fund | 156 | 0.01% | ₹50,000 |
| Angel One Nifty Total Market ETFAngel One Mutual Fund | 152 | 0.01% | ₹48,670 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Suven Life Sciences insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 1 off-market move
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Suven Life Sciences competitors and peers
Healthcare Research, Analytics & Technology, 11 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Suven Life Sciences in market cap.Healthcare companies
Suven Life Sciences is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Syngene InternationalSYNGENE | 14,782 | 79.43 | 3.04 | −6.0% | −60.3% | 3.9% | 6.1% | 0.34% |
 IndegeneINDGN | 14,457 | 36.06 | 4.61 | +30.4% | −7.9% | 13.9% | 15.6% | 0.38% |
 Vimta LabsVIMTALABS | 2,275 | 28.56 | 4.98 | +15.2% | – | 19.1% | 21.4% | 0.39% |
 BilcareBI | 195 | – | 0.99 | −0.9% | – | – | 5.4% | 0.00% |
 Novelix PharmaceuticalsNOVELIX | 171 | 47.10 | – | +179.9% | – | 11.3% | 8.7% | 0.00% |
 Jeevan Scientific TechnologyJSTL | 166 | – | 2.31 | +66.1% | – | – | 8.8% | 0.00% |
 TAKETAKE | 150 | 11.70 | 4.84 | – | −68.2% | 49.8% | −5.6% | 0.00% |
 GlobalSpace Technologies540654 | 78 | – | 1.38 | +37.2% | – | – | 7.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Suven Life Sciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.50 a share, years to Mar 2018 and Mar 2019.
| Ex-date | Type | Per share |
|---|---|---|
| 14 Feb 2019 | Interim | ₹1.50 |
| 6 Feb 2018 | Interim | ₹1.50 |
| 8 Feb 2017 | Interim | ₹1.00 |
| 14 Mar 2016 | Interim | ₹1.00 |
| 14 Mar 2016 | Special | ₹1.00 |
| 23 Jul 2015 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.60 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Suven Life Sciences announcements
Sep 2026
Aug 2026
11 Aug · Business
6 Aug · Results
Jul 2026
30 Jul · Board meeting
30 Jul · General Updates
Suven Life Sciences share price by year
Each calendar year to 2025.Suven Life Sciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 166.27 | +30.0% | 296.60 | 104.16 |
| 2024 | 127.92 | +58.4% | 164.66 | 82.15 |
| 2023 | 80.75 | +18.0% | 86.15 | 45.50 |
| 2022 | 68.45 | −23.2% | 101.55 | 59.85 |
| 2021 | 89.10 | −1.6% | 120.15 | 70.65 |
| 2020Demerger | 90.55 | −70.5% | 316.10 | 15.95 |
| 2019 | 307.10 | +35.6% | 320.30 | 186.60 |
| 2018 | 226.55 | +11.4% | 319.40 | 167.35 |
| 2017 | 203.40 | +17.6% | 223.25 | 156.20 |
| 2016 | 172.90 | −34.9% | 264.40 | 146.40 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. With the demerger of 21 Jan 2020 reinvested, the change in 2020 is +484.8%.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 261.50 | 269.90 | 258.55 | 262.00 | 264.54 | 6,41,743 | 45.6% |
| 23 Oct 2026 | 268.20 | 271.20 | 256.60 | 261.35 | 261.95 | 10,72,068 | 41.2% |
| 22 Oct 2026 | 274.00 | 278.20 | 266.85 | 268.20 | 271.20 | 6,42,916 | 46.5% |
| 21 Oct 2026 | 290.70 | 292.85 | 276.65 | 278.65 | 281.24 | 4,23,773 | 59.8% |
| 19 Oct 2026 | 303.95 | 304.35 | 288.40 | 290.05 | 292.57 | 3,53,639 | 47.5% |
| 16 Oct 2026 | 304.00 | 308.85 | 298.10 | 303.55 | 304.42 | 5,27,969 | 36.3% |
| 15 Oct 2026 | 285.65 | 311.00 | 285.25 | 300.25 | 302.99 | 35,61,664 | 17.5% |
| 14 Oct 2026 | 283.75 | 292.00 | 278.45 | 285.45 | 282.93 | 3,73,206 | 44.8% |
| 13 Oct 2026 | 287.95 | 289.85 | 276.50 | 283.75 | 282.78 | 5,49,868 | 39.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 17 Oct 2022 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 21 Jan 2020 | Demerger | 0.0504 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
| 23 Mar 2007 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 23 Mar 2007 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- SUVEN
- BSE code
- 530239
- ISIN
- INE495B01038
- Industry
- Healthcare Services
- Website
- www.suven.com
- CIN
- L24110TG1989PLC009713
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1989
- Registered office
- 8-2-334, Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad 500034, Telangana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments